"uuid:ID","versionIdentifier","id","rationale","instanceType"
"5b11cc6c-3ec1-4bea-b469-51cefea2e61a","2","StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion"
